The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.
Open accessAbstract
The antitumor effect and mechanisms activated by murine IL-12 and IL-18, cytokines that induce IFN-gamma production, were studied using engineered SCK murine mammary carcinoma cells. In syngeneic A/J mice, SCK cells expressing mIL-12 or mIL-18 were less tumorigenic and formed tumors more slowly than control cells. Neither SCK.12 nor SCK.18 cells protected significantly against tumorigenesis by distant SCK cells. However, inoculation of the two cell types together synergistically protected 70% of mice from concurrently injected distant SCK cells and 30% of mice from SCK cells established 3 d earlier. Antibody neutralization studies revealed that the antitumor effects of secreted mIL-12 and mIL-18 required IFN-gamma. Interestingly, half the survivors of SCK.12 and/or SCK.18 cells developed protective immunity suggesting that anti-SCK immunity is unlikely to be responsible for protection. Instead, angiogenesis inhibition, assayed by Matrigel implants, appeared to be a property of both SCK.12 and SCK.18 cells and the two cell types together produced significantly greater systemic inhibition of angiogenesis. This suggests that inhibition of tumor angiogenesis is an important part of the systemic antitumor effect produced by mIL-12 and mIL-18.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Cloning of a new cytokine that induces IFN-γ production by T cells
Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995) · Nature · doi:10.1038/378088a0 · Cited by 2,600
Trinchieri, G. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.001343 · Cited by 2,399
Self-citationKleinman, H. K., McGarvey, M. L., Liotta, L. A., Robey, P. G., Tryggvason, K., & Martin, G. R. (1982) · Biochemistry · doi:10.1021/bi00267a025 · Cited by 1,231
Xie, Q. W., Whisnant, R., & Nathan, C. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1779 · Cited by 1,118
Passaniti, A., Taylor, R. M., Пили, Р., Guo, Y., Long, P., Haney, J. A., Pauly, R. R., Grant, D. S., & Martin, G. R. (1992) · PubMed · Cited by 806
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
The Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410
Interleukin-18 Regulates Both Th1 and Th2 Responses
Nakanishi, K., Yoshimoto, T., Tsutsui, H., & Okamura, H. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.423 · Cited by 1,315
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Kamihata, H., Matsubara, H., Nishiue, T., Fujiyama, S., Tsutsumi, Y., Ozono, R., Masaki, H., Mori, Y., Iba, O., Tateishi, E., et al. (2001) · Circulation · doi:10.1161/hc3501.093817 · Cited by 965
The roles of IFNγ in protection against tumor development and cancer immunoediting
Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00038-7 · Cited by 899
IL-18: A TH1 -inducing, proinflammatory cytokine and new member of the IL-1 family
Dinarello, C. A. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70518-x · Cited by 819
CXC chemokines in angiogenesis
Belperio, J. A., Keane, M. P., Arenberg, D. A., Addison, C. L., Ehlert, J. E., Burdick, M. D., & Strieter, R. M. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.1.1 · Cited by 804
(2000) · PubMed · Cited by 706
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
Self-citationNAKANISHI, K., YOSHIMOTO, T., TSUTSUI, H., & OKAMURA, H. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00015-0 · Cited by 662
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
Interleukin-12: Biological Properties and Clinical Application
Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M. T., Wesa, A., Parmiani, G., & Anichini, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0776 · Cited by 601
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
Cytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Zaki, M. H., Vogel, P., Body-Malapel, M., Lamkanfi, M., & Kanneganti, T.-D. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002046 · Cited by 411
Doyle, S. L., Campbell, M., Ozaki, E., Salomon, R. G., Mori, A., Kenna, P. F., Farrar, G. J., Kiang, A.-S., Humphries, M. M., Lavelle, E. C., et al. (2012) · Nature Medicine · doi:10.1038/nm.2717 · Cited by 422
CXC chemokines in angiogenesis
Strieter, R. M., Burdick, M. D., Gomperts, B. N., Belperio, J. A., & Keane, M. P. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.04.007 · Cited by 414
Cytokines in cancer immunity and immunotherapy
Smyth, M. J., Cretney, E., Kershaw, M. H., & Hayakawa, Y. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00199.x · Cited by 412
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
Dinarello, C. A. (1999) · Methods · doi:10.1006/meth.1999.0837 · Cited by 369
Chmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
IL-18 regulates IL-1 β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1
Vidal-Vanaclocha, F., Fantuzzi, G., Mendoza, L., Fuentes, A. M., Anasagasti, M. J., Martín, J., Carrascal, T., Walsh, P., Reznikov, L. L., Kim, S.-H., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.734 · Cited by 338
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis
Dirkx, A. E. M., oude Egbrink, M. G. A., Wagstaff, J., & Griffioen, A. W. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0905495 · Cited by 326
Coughlin, C. M., Salhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J. E., Liu, L., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80585-3 · Cited by 324
Self-citationSchey, S. A., Fields, P., Bartlett, J. B., Clarke, I. A., Ashan, G., Knight, R. D., Streetly, M., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 314
Inflammatory cell infiltration of tumors: Jekyll or Hyde
Talmadge, J. E., Donkor, M., & Scholar, E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9072-0 · Cited by 313
Lertmemongkolchai, G., Cai, G., Hunter, C. A., & Bancroft, G. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.1097 · Cited by 302
Self-citationThe NLRP3 inflammasome: Contributions to intestinal homeostasis
Zaki, M. H., Lamkanfi, M., & Kanneganti, T.-D. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.02.002 · Cited by 290
Cheng, W.-F., Hung, C.-F., Chai, C.-Y., Hsu, K.-F., He, L., Ling, M., & Wu, T.-C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12346 · Cited by 281
Tumors and inflammatory infiltrates: Friends or foes?
Brigati, C., Noonan, D. M., Albini, A., & Benelli, R. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1015587423262 · Cited by 230
Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages
Stout, R. D., Watkins, S. K., & Suttles, J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0209073 · Cited by 183
IL-12 attenuates bleomycin-induced pulmonary fibrosis
Keane, M. P., Belperio, J. A., Burdick, M. D., & Strieter, R. M. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.281.1.l92 · Cited by 146
Dual biological effects of the cytokines interleukin-10 and interferon-γ
Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138
Addison, C. L., Arenberg, D. A., Morris, S. B., Xue, Y.-Y., Burdick, M. D., Mulligan, M. S., Iannettoni, M. D., & Strieter, R. M. (2000) · Human Gene Therapy · doi:10.1089/10430340050015996 · Cited by 136
Interleukin-18 (IL-18) Enhances Innate IL-12-Mediated Resistance to Toxoplasma gondii
Cai, G., Kastelein, R., & Hunter, C. A. (2000) · Infection and Immunity · doi:10.1128/iai.68.12.6932-6938.2000 · Cited by 116
Self-citationTumor-Associated Macrophages as Targets for Cancer Therapy
Wahl, L. M., & Kleinman, H. K. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1583 · Cited by 110
Duan, X., Guan, H., Cao, Y., & Kleinerman, E. S. (2009) · Cancer · doi:10.1002/cncr.24013 · Cited by 79
(2001) · PubMed · Cited by 61
Environmental stimuli shape microglial plasticity in glioma
Garofalo, S., Porzia, A., Mainiero, F., Di Angelantonio, S., Cortese, B., Basilico, B., Pagani, F., Cignitti, G., Chece, G., Maggio, R., et al. (2017) · eLife · doi:10.7554/elife.33415 · Cited by 58
IL-12 Regulates an Endothelial Cell-Lymphocyte Network: Effect on Metalloproteinase-9 Production
Mitola, S., Strasly, M., Prato, M., Ghia, P., & Bussolino, F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3725 · Cited by 58
Metadata
- Authors
- Coughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., Hunter, C. A., Fox, J. C., Trinchieri, G., & Lee, W. M.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-03-15
- Volume
- 101
- Issue
- 6
- Pages
- 1441-1452
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2149579127
- Cited by
- 415
- References
- 40
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.